Thermo Fisher Scientific Announces Launch of Immune Cell Types Family of Assays

Applied Biosystems PureQuant Assays are a family of assays that accurately identify and quantify specific immune cell types in a mixed population of cells. Designed for in-process and release testing of cell-based therapeutics, these assays measure genomic DNA methylation at sites that are unique to a specific immune cell type. With standards and controls built into each assay, they are ready to be seamlessly integrated into cell therapy workflows.

With the launch of the Applied Biosystems PureQuant Assays, Thermo Fisher Scientific has enhanced its industry-leading cell and gene therapy portfolio by providing an innovative method for identity and purity testing of cell-based therapeutics.

Features/Benefits:
• Proven performance: The core technology has been used for identification and quantification of immune cell types for more than a decade.
• Easily standardized: The qPCR method enables consistent results across multiple users, instruments and sites.
• Facilitates regulatory filings: Regulatory support file provided upon request; established performance specifications following ICHQ2(R1) guidelines.
• Scheduling flexibility: The assay can be performed using fresh or frozen cells/gDNA.